Get the Stockscreener App
3.845
4.48%
0.165
Evoke Pharma Inc stock is traded at $3.845, with a volume of 13,349.
It is up +4.48% in the last 24 hours and down -28.80% over the past month.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
See More
Previous Close:
$3.68
Open:
$3.8
24h Volume:
13,349
Relative Volume:
0.74
Market Cap:
$5.71M
Revenue:
$8.62M
Net Income/Loss:
$-6.15M
P/E Ratio:
-0.3486
EPS:
-11.03
Net Cash Flow:
$-5.32M
1W Performance:
-4.92%
1M Performance:
-28.80%
6M Performance:
-10.79%
1Y Performance:
-50.01%
1-Day Range:
$3.67
$3.9107
1-Week Range:
$3.60
$4.04
52-Week Range:
$3.44
$12.32
Evoke Pharma Inc Stock (EVOK) Company Profile
Name
Evoke Pharma Inc
Sector
Phone
858-345-1494
Address
420 STEVENS AVENUE, SOLANA BEACH, CA
Compare EVOK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVOK
Evoke Pharma Inc
|
3.845 | 5.71M | 8.62M | -6.15M | -5.32M | -11.03 |
|
ZTS
Zoetis Inc
|
160.06 | 71.67B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 47.44B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.19 | 46.08B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.46 | 18.86B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.36 | 13.97B | 612.78M | -86.37M | -62.91M | -0.87 |
Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-22-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-05-19 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-08-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Oct-19-17 | Resumed | FBR & Co. | Buy |
| Mar-16-17 | Reiterated | Rodman & Renshaw | Buy |
| Jan-30-17 | Upgrade | Laidlaw | Neutral → Buy |
| Jan-05-17 | Upgrade | Rodman & Renshaw | Neutral → Buy |
| Dec-23-16 | Reiterated | Rodman & Renshaw | Neutral |
| Jul-19-16 | Reiterated | FBR Capital | Outperform |
| Jul-19-16 | Downgrade | Noble Financial | Buy → Hold |
| Jul-18-16 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Mar-16-16 | Initiated | Northland Capital | Outperform |
| Mar-14-16 | Reiterated | Ascendiant Capital Markets | Buy |
| Feb-17-16 | Resumed | FBR Capital | Outperform |
| Dec-03-14 | Reiterated | MLV & Co | Buy |
| Nov-07-14 | Initiated | MLV & Co | Buy |
| Apr-22-14 | Initiated | Laidlaw | Buy |
| Nov-19-13 | Initiated | Aegis Capital | Buy |
View All
Evoke Pharma Inc Stock (EVOK) Latest News
Evoke Pharma Inc (EVOK) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Growth Plans - Yahoo Canada Finance
Evoke Pharma Reports Strong Revenue Growth in 2024 - TipRanks
Earnings call transcript: Evoke Pharma Q4 2024 reports strong sales growth - Investing.com
Evoke Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Marketscreener.com
EVOKE PHARMA Earnings Results: $EVOK Reports Quarterly Earnings - Nasdaq
Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
The Canada Foundation for Innovation supports Canada Research Chairs with nearly $4.4 million investment in research infrastructure - The Manila Times
Earnings Scheduled For March 13, 2025 - Benzinga
StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK) - Defense World
Gastroparesis Treatment Market Poised for Substantial Growth - openPR
Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025 - GlobeNewswire
Evoke Pharma, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025 - Nasdaq
When Will Evoke Pharma Share Its Latest Gimoti Sales Numbers? - StockTitan
Evoke Pharma (EVOK) to Release Quarterly Earnings on Wednesday - Defense World
Sanctuary Advisors LLC Sells 40,570 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) - Defense World
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Sanctuary Advisors LLC - Defense World
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Sanctuary Advisors LLC - Defense World
Evoke Pharma (NASDAQ:EVOK) Stock Crosses Below 200 Day Moving Average – Should You Sell? - Defense World
Alliance Bioenergy Plus (OTCMKTS:ALLM) Shares Cross Below 200 Day Moving Average – Time to Sell? - Defense World
Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com - Defense World
Evoke Pharma stock hits 52-week low at $3.49 amid challenges - Investing.com India
Evoke Pharma stock hits 52-week low at $3.49 amid challenges By Investing.com - Investing.com South Africa
Evoke Pharma, Inc. to Host Earnings Call - ACCESS Newswire
Investor Network: Evoke Pharma, Inc. to Host Earnings Call - ACCESS Newswire
Gastroparesis Drugs Market Forecast: Insights, Trends & Key - openPR
Diabetic Gastroparesis Treatment Market Future Business - openPR
Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com - Armenian Reporter
Evoke Pharma adds pharma veteran to its board - Investing.com
Evoke Pharma adds pharma veteran to its board By Investing.com - Investing.com South Africa
Evoke Pharma appoints new director Greg Pyszcymuka - Investing.com
5 Top AI Stocks I'm Buying on the Dip - The Globe and Mail
Evoke Pharma appoints new director Greg Pyszcymuka By Investing.com - Investing.com South Africa
Evoke Pharma, Inc. Appoints Greg Pyszczymuka to Board of Directors, Strengthening Commercial Strategy - Nasdaq
Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors - GlobeNewswire
Can This New Board Member Transform Evoke Pharma's Commercial Success? - StockTitan
(EVOK) Investment Analysis and Advice - Stock Traders Daily
Geriatric Medicines Market Poised for Significant Expansion | - openPR
Gastric Motility Disorder Drug Market Witnessing High Demand | - openPR
Evoke Pharma (NASDAQ:EVOK) Coverage Initiated by Analysts at StockNews.com - Defense World
Gastroparesis Drugs Market: $6,662.35 Million by 2032, 4.4% CAGR - openPR
Gastroparesis Treatment Market Generated Opportunities, - openPR
Evoke Pharma (NASDAQ:EVOK) Now Covered by StockNews.com - Defense World
Loss-Making Evoke Pharma, Inc. (NASDAQ:EVOK) Set To Breakeven - Simply Wall St
Research Analysts’ New Coverage for February 8th (AC, APT, ARL, BIOL, CCRN, CNET, EDAP, ENLC, ENSV, ESGR) - Armenian Reporter
Gastroparesis Market Expected to rise, 2034 | Vanda - openPR
Nantahala Capital Management, LLC Increases Stake in Evoke Pharm - GuruFocus.com
Evoke Pharma (NASDAQ:EVOK) Stock Crosses Below 200 Day Moving Average – Here’s What Happened - Defense World
StockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK) - Defense World
Nantahala Capital Management, LLC Reduces Stake in Evoke Pharma Inc - GuruFocus.com
Trane Technologies (TT) Reports Q4: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
VF Corp (VFC) Reports Q4: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
Evoke Pharma Inc Stock (EVOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.77%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):